Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: A Northern Region Lymphoma Group study (UK)

Annals of Oncology

Volumn 14, Issue SUPPL. 1, 2003, Pages

  Proctor, S J ^a   Jackson, G H ^b   Lennard, A ^b   Angus, B ^b   Wood, K ^b   Lucraft, H L ^b   White, J ^b   Windebank, K ^b   Taylor, P R A ^b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; DACARBAZINE; DIURETIC AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; ONDANSETRON; PREDNISOLONE; PROCARBAZINE; VINBLASTINE;

ADULT; ALOPECIA; ARTICLE; AUTOTRANSPLANTATION; BLOOD TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; EDEMA; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SALVAGE THERAPY; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0038511311     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg710     Document Type: Article

References (10)

1. Proctor SJ, Mackie M, Dawson A et al. A population-based study of intensive multi-agent chemotherapy with or without aututransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002; 38: 795-806.
2. Diehl V, Franklin J, Hasenclever D. On behalf of the German Hodgkin's Lymphoma Study Group. BEACOPP, a new dose-escalated and accelerated regimen is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma. J Clin Oncol 1998; 16: 3810-3821.
3. Jackson GH, Angus B, Carey PJ et al. High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. Leuk Lymphoma 2000; 37: 561-570.
4. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneve, Switzerland: World Health Organization 1979.
5. Taylor PRA, Jackson GH, Lennard AL et al. on behalf of the Newcastle and Northern Region Lymphoma Group. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. Br J Cancer 1993; 67: 383-387.
6. Moskowitz CH, Nimer SD, Zelenetz AD et al. A two-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin's disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
7. Ferme C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995; 6: 543-549.
8. Proctor SJ, Rueffer JU, Angus B et al. Hodgkin's disease in the elderly: current status and future directions. Ann Oncol 2002; 13 (Suppl 1): 133-137.
9. Stark GL, Wood KM, Jack F et al. On behalf of the Northern Region Lymphoma Group. Hodgkin's disease in the elderly: a population-based study. Br J Haematol 2002; 119: 432-440.
10. Proctor SJ, Taylor P, Donnan P et al. A numerical prognostic index for clinical use in identification of poor risk patients with Hodgkin's disease at diagnosis. Eur J Cancer 1991; 27: 624-629.